Medical Oncology

, Volume 29, Issue 4, pp 2606–2612 | Cite as

P-cadherin expression and basal-like subtype in breast cancers

  • N. Liu
  • Q. Yu
  • T. J. Liu
  • Estifanos P. Gebreamlak
  • S. L. Wang
  • R. J. Zhang
  • J. Zhang
  • Y. Niu
Original Paper
First Online:
Received:
Accepted:

Abstract

Breast cancer is considered as one of the multifactorial diseases. The aim of the current study is to investigate the association between P-cadherin and molecular subtypes of breast cancer, especially the basal-like subtype. Two hundred and thirteen breast–invasive ductal carcinomas were involved in this study. The expressions of P-cadherin were detected via immunohistochemistry. The 213 cases were divided into luminal A, luminal B, HER2 overexpression subtype, and normal breast-like and basal-like subtypes according to the standard of molecular breast cancer subtypes. In addition, the expressions of CK5/6 and CK14 were detected to distinguish between the normal breast-like and the basal-like subtypes. P-cadherin expression was found in 91 cases of 213 breast–invasive ductal carcinomas, with a positive rate of 42.7 %. P-cadherin correlated negatively with estrogen receptor (ER) (p = 0.001) and progesterone receptor (p = 0.001), whereas it positively correlated with histologic grade (p = 0.003), NPI (p = 0.005), p53 (p = 0.038), and Ki67 (p = 0.022). P-cadherin expression showed a strong correlation with recurrence and distant metastasis (p = 0.009), and invasion of the vascular and soft tissues (p = 0.004). Moreover, P-cadherin expression existed in the basal-like and non-basal-like subtypes. During prognosis, P-cadherin expression was associated with decreased disease-free survival in patients (p = 0.009) and overall survival (OS) (p = 0.005). In addition, multivariate analysis showed that tumor grade (p = 0.021), ER (p = 0.015), clinical stage (p = 0.001), and P-cadherin (p = 0.033) were significant predictors of OS. The current data suggest that P-cadherin may be used to distinguish the basal-like subtype and to predict the outcome in view of the relationship with DFS and OS. Furthermore, P-cadherin expression may be useful in making treatment decisions.

Keywords

P-cadherin Basal-like subtype Breast cancer 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Liu H, Xun P, Chen K-x, et al. The trend of clinical characteristics and prognosis of women’s breast cancer 1981–2000. Natl Med J China. 2007;87(34):2405–7.Google Scholar
  2. 2.
    Alizadeh AA, Ross DT, Perou CM, et al. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol. 2001;195:41–52.PubMedCrossRefGoogle Scholar
  3. 3.
    Reis-Filho JS, Simpson PT, Gale T, et al. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol Res Pract. 2005;201:713–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Lacroix M, Toillon RA, Leclercq G. Stable ‘portrait’ of breast tumors during progression: data from biology, pathology and genetics. Endocr Relat Cancer. 2004;11:497–522.PubMedCrossRefGoogle Scholar
  5. 5.
    Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205:248–54.PubMedCrossRefGoogle Scholar
  6. 6.
    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.PubMedCrossRefGoogle Scholar
  7. 7.
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.PubMedCrossRefGoogle Scholar
  9. 9.
    van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.CrossRefGoogle Scholar
  10. 10.
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678–85.PubMedCrossRefGoogle Scholar
  12. 12.
    Rakha EA, El-Sayed ME, Green AR, et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology. 2007;50:434–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 2006;8:R34.PubMedCrossRefGoogle Scholar
  14. 14.
    Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Jumppanen M, Gruvberger-Saal S, Kauraniemi P, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res. 2007;9:R16.PubMedCrossRefGoogle Scholar
  16. 16.
    Tang P, Wei B, David G, et al. Breast cancer molecular subtypes and clinical application. Chin J Pathol. 2009;38:13–7.Google Scholar
  17. 17.
    Sousa B, Paredes J, Milanezi F, et al. P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. Histol Histopathol. 2010;25(8):963–74.PubMedGoogle Scholar
  18. 18.
    Turashvili G, McKinney SE, Goktepe O, et al. P-cadherin expression as a prognostic biomarker in a 3,992 case tissue microarray series of breast cancer. Mod Pathol. 2011;24(1):64–81.PubMedCrossRefGoogle Scholar
  19. 19.
    Knudsen KA, Wheelock MJ. Cadherins and the mammary gland. J Cell Biochem. 2005;95:488–96.PubMedCrossRefGoogle Scholar
  20. 20.
    Rakha EA, Putti TC. Abd El-Rehim DM, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495–506.PubMedCrossRefGoogle Scholar
  21. 21.
    Tavassoli FA, Devilee P, editors. The WHO classification of tumors of the breast and female genital organs (M). Lyon: IARC Press; 2003. p. 10–112.Google Scholar
  22. 22.
    Miller DV, Leontovich AA, Lingle WL, et al. Utilizing Nottingham prognostic index in microarray gene expression profiling of breast carcinomas. Mod Pathol. 2004;17:756–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology. 2009;41:40–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Paredes J, Albergaria A, Oliveira JT, et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005;11:5869–77.PubMedCrossRefGoogle Scholar
  25. 25.
    Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005;447:688–94.PubMedCrossRefGoogle Scholar
  26. 26.
    Paredes J, Correia AL, Ribeiro AS, et al. P-cadherin expression in breast cancer: a review. Breast Cancer Res. 2007;9:214.PubMedCrossRefGoogle Scholar
  27. 27.
    Van Marck V, Stove C, Van Den Bossche K, et al. P-cadherin promotes cell–cell adhesion and counteracts invasion in human melanoma. Cancer Res. 2005;65:8774–83.PubMedCrossRefGoogle Scholar
  28. 28.
    Madhavan M, Srinivas P, Abraham E, et al. Cadherins as predictive markers of nodal metastasis in breast cancer. Mod Pathol. 2001;14:423–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Kovacs A, Dhillon J, Walker RA. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Mol Pathol. 2003;56:318–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Paredes J, Stove C, Stove V, et al. P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res. 2004;64:8309–17.PubMedCrossRefGoogle Scholar
  31. 31.
    Albergaria A, Ribeiro AS, Pinho S, et al. ICI 182,780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation. Hum Mol Genet. 2010;19(13):2554–66.PubMedCrossRefGoogle Scholar
  32. 32.
    Ribeiro AS, Albergaria A, Sousa B, et al. Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene. 2010;29(3):392–402.PubMedCrossRefGoogle Scholar
  33. 33.
    Sarrió D, Palacios J, Hergueta-Redondo M, et al. Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer. 2009;3(9):74.CrossRefGoogle Scholar
  34. 34.
    Liu N, Niu Y, Wang SL, et al. Diagnostic and prognostic significance of FOXA1 expression in molecular subtype of breast invasive ductal carcinoma. Zhonghua Yi Xue Za Zhi. 2010;90(20):1403–7.Google Scholar
  35. 35.
    Niu Y. Basal-like carcinoma: one subtype of breast cancer recognized recently. Chin J Pathol. 2007;36:849–52.Google Scholar
  36. 36.
    Yang GZ, Gao LX, Ding HY. Basal-like subtype of breast cancer. Chin J Diag Pathol. 2007;14:241–3.Google Scholar
  37. 37.
    Gao LX, Yang GZ, Ding HY, et al. Morphological features of basal-like subtype invasive carcinoma of breast. Chin J Pathol. 2008;37:83–7.Google Scholar
  38. 38.
    Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11:4003–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • N. Liu
    • 1
    • 2
  • Q. Yu
    • 1
    • 3
  • T. J. Liu
    • 4
  • Estifanos P. Gebreamlak
    • 1
  • S. L. Wang
    • 1
  • R. J. Zhang
    • 1
  • J. Zhang
    • 1
  • Y. Niu
    • 1
  1. 1.Breast Cancer Research Key Laboratory of National Education Ministry, Ministry of Education and Key Laboratory of Cancer Prevention and Therapy, Cancer Institute and HospitalTianjin Medical UniversityHe Xi District, TianjinChina
  2. 2.Baodi Clinical College of Tianjin Medical UniversityTianjinChina
  3. 3.Department of OncologyJinghai HospitalTianjinChina
  4. 4.Department of PathologyTianjin Medical UniversityTianjinChina

Personalised recommendations